Teva Presents Real-World AUSTEDO Data Showing Quality-of-Life Gains in Huntington's Disease Chorea

Real-world evidence from Teva Pharmaceuticals is adding patient- and caregiver-reported weight to the clinical profile of AUSTEDO and AUSTEDO XR (deutetrabenazine), with findings from the first decentralized survey of its kind presented at the Advanced Therapeutics in Movement & Related Disorders Congress in Washington, DC, June 4–8, 2026.

The survey, conducted through the myHDstory® platform, enrolled self-reporting HD chorea patients (≥18 years) in the United States alongside caregivers of individuals with HD chorea. Pre-treatment data showed chorea interfering with social life in 71–84% of patients and affecting caregiver social functioning in 73–84% of respondents, a burden profile that contextualises the therapeutic target beyond movement suppression alone.

Post-treatment findings among patients taking AUSTEDO or AUSTEDO XR were consistent across multiple quality-of-life domains. 74% of patients reported chorea movement improvement on the Patient Global Impression of Change (PGIC) scale; over 85% reported gains in daily activity goals such as dressing, walking, and eating, as well as social goals including outings with family and friends. Between 60–71% of patients reported improvement across multiple quality-of-life domains attributable to reduced chorea. Separately, 77% of caregivers reported reduced impact on their own daily lives following the patient's treatment initiation.

For formulators and manufacturing leads, the AUSTEDO XR extended-release profile is relevant context here. Modified-release deutetrabenazine requires controlled dissolution engineering to maintain consistent plasma exposure across a once-daily dosing interval, a design choice with direct implications for patient adherence and, by extension, the real-world outcomes this survey captures. Sustained adherence to a simplified regimen is a known variable in chronic CNS disease management, and the survey's PGIC-based methodology provides a structured instrument for tracking that relationship outside controlled trial conditions.

The non-interventional, decentralized study design, using an online platform rather than site-based enrollment, reflects a broader methodological shift in real-world evidence generation, one that 21 CFR Part 312 and evolving FDA guidance on real-world data are increasingly accommodating for post-approval characterisation of patient-reported outcomes.

Teva's Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer, noted that the data reinforce how deeply HD chorea affects patients physically, emotionally, and functionally, and the corresponding strain on care partners.

The next measurable checkpoint will be whether Teva submits these real-world findings to support label updates or post-marketing commitments tied to AUSTEDO XR's modified-release formulation profile.

Source: Teva Pharmaceuticals via GlobeNewswire, June 5, 2026. Data presented at the Advanced Therapeutics in Movement & Related Disorders Congress, Washington, DC, June 4–8, 2026.